Competitive Technologies Obtains Exclusive Rights To Patented, Innovative Cancer Treatment From the University of SC

Competitive Technologies Obtains Exclusive Rights To Patented, Innovative
Cancer Treatment

FAIRFIELD, Conn., Feb. 24 /PRNewswire-FirstCall/ -- Competitive
Technologies, Inc. (Amex: CTT) announced today that it has signed an exclusive
agreement with the University of South Carolina Research Foundation (USCRF) to
license and commercialize their patented anti-cancer treatment with
dual-action capability against tumor growth. The treatment is the result of
the research of the renowned Dr. Roy E. Wuthier, the Guy Lipscomb Professor of
Biochemistry, of the Chemistry and Biochemistry Department at the University
of South Carolina.
The compound possesses a potent anticancer activity against a variety of
human tumor cells with low toxicity to normal cells. Studies conducted by
researchers at the University and at the National Cancer Institute have shown
the technology to be effective against a variety of human tumor cell lines at
concentrations in the nanomolar range. The small molecular weight compound is
orally available and is effective in inhibiting angiogenesis. Angiogenesis is
the formation of new capillary blood vessels that support tumor development
and metastasis. The anti-angiogenesis applications of this compound include
development of chemotherapeutic agents for the treatment of angiogenic
diseases such as cancer, psoriasis, diabetic retinopathy, and various other
vascularization-related eye disorders. The technology is covered in the US by
Patents 5,932,611, 6,225,340 and 6,660,765, and internationally by PCT Patent
749,021.
"CTT is proud to continue our relationship with the University of South
Carolina with this unique cancer-fighting technology," said Suzanne N. B.
Alent, CTT's VP Marketing and Business Development. "It is particularly
attractive for drug development because of its multiple capabilities and
strong performance against various diseases. We look forward to working
closely with both Dr. Wuthier and Dr. Brian Genge, a research professor at the
University, in developing this technology."
"This agreement is further evidence of the progress CTT and its team are
making in building a strong portfolio of innovative and commercially viable
technologies," said John B. Nano, CTT's President and CEO. "CTT's team is
actively marketing and commercializing our technologies including
nanotechnology bone biomaterial, wound sealant, language-mastering software,
silicon carbide wafer testing, pollution abatement, insulated concrete forms
and automotive safety sensors. Utilizing this portfolio to satisfy customer
needs, CTT is building a recurring revenue stream and strengthening
shareholder value."

About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, is a full service
technology transfer and licensing provider focused on the technology needs of
its customers and transforming those requirements into commercially viable
solutions. CTT is a global leader in identifying, developing and
commercializing innovative technologies in life, digital, nano, and physical
sciences developed by universities, companies and inventors. The global market
for technology transfer services is estimated at $150 billion annually. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: http://www.competitivetech.net

Statements about the Company's future expectations, including development
and regulatory plans, and all other statements in this document other than
historical facts are "forward-looking statements" within the meaning of
applicable Federal Securities Laws and are not guarantees of future
performance. These statements involve risks and uncertainties, including those
set forth in Item 1 of the Company's most recent Form 10-K and in CTT's other
filings with the SEC, and are subject to change at any time. The Company's
actual results could differ materially from these forward-looking statements.
The Company undertakes no obligation to update publicly any forward-looking
statement.

Direct inquiries to: Johnnie D. Johnson, Strategic IR, Inc.
Tel. (212) 754-6565; Fax (212) 754-4333
E-mail: [email protected]
E-mail: [email protected]

SOURCE Competitive Technologies, Inc.
Web Site: http://www.competitivetech.net

See 11349 other posts submitted by John Warner. Find articles, people, and videos related to: General Archives